Umoja Biopharma

Congratulations to our co-founder Ryan Crisman on his selection to the Board of Directors of the Colorado BioScience Association. CBSA has been an exceptional local partner for our Louisville team as we took our CLIMB facility from initial ideation through what it is today: a site with global reach that is generating GMP drug product for our clinical trials and future patients.

Last week, we were excited to welcome 29 talented high school juniors to our Louisville Colorado facility for an inspiring Pathways in Technology Early College (P-TECH) day. Our team had the privilege of showing these budding scientists how our core values of joyfulness and making a meaningful impact come together in our daily mission of changing the future of how we treat cancer. Our own Kate Knights said "P-TECH is an incredible opportunity that I wish I had when I was in high school. The connection that students and industry mentors build is such a powerful resource to help them navigate their future. The internships they participate in with P-TECH help open their eyes to the work force that few others at their age get to experience. It is truly an astounding program to be a part of and see grow over the last five years." Through P-TECH's public-private partnership model, we are excited to welcome four of these promising students this summer for internships, continuing our commitment to nurturing the next generation of scientific talent. A big thank you to the Colorado BioScience Institute for this opportunity!

At Umoja Biopharma, we are proud to celebrate International Day of Women and Girls in Science by sharing stories from some of our own remarkable women here at Umoja. The beginning of a career dedicated to scientific curiosity can often be a memorable experience. At Umoja, that experience for Kristen Mittelsteadt, PhD included monitoring salmon development in 6th grade. For Kacie Breeding, it was a Systems Physiology class that revealed how bodies tell stories. To the next generation of women scientists, our team offers wisdom from their own experiences. Sarah Gould says, "Find your community, those who believe in your potential. Your ideas and contributions matter, your voice matters." Susana Hernandez also shared that "being a Mexican immigrant and a mother of two," she "aims to challenge stereotypes and open doors for future generations, particularly those from underserved communities." At Umoja, we're harnessing the power of the immune system to fight cancer, but we're also fostering an environment where diverse perspectives drive our innovation. Today and every day, we celebrate the women who have made and continue to make our mission possible.

We are excited to welcome Dr. Luke Walker as Chief Medical Officer of Umoja! Dr. Walker brings more than 20 years of hematology and clinical development experience to the role, and will be responsible for the leadership of Umoja’s clinical, regulatory, and medical functions, including our two clinical stage in vivo CAR T cell programs UB-VV111 and UB-VV400 in B cell malignancies. Full details: https://lnkd.in/eCcy35-y

This morning we announced a $100M Series C fundraise to support the continued development of our in vivo CAR T cell therapy pipeline, including our lead CD22 candidate UB-VV400. Full details are below, and please join us at the J.P. Morgan Healthcare Conference tomorrow for more details: https://lnkd.in/ggSHXXqM

Please join us at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday next week. Our co-founder and CEO Andy Scharenberg will share updates and progress of our in vivo CAR T cell programs as part of a catalyst-rich 2025 and beyond. https://lnkd.in/g_WiupxP

Our COO David Fontana was recently invited to share the promise of our VivoVec in vivo CAR T programs in Drug Target Review. Our unique approach of uniting our industry-leading in vivo science with the expertise and control of in-house manufacturing aims to improve the effectiveness and access of CAR T cells—and ultimately transform the outcomes of our patients. Follow the link here to read more: https://lnkd.in/gnhPskqc

We were honored to host Brad Loncar with BiotechTV at our SKI site in Seattle yesterday. In the full video linked below, our co-founder and CEO Andy Scharenberg shares the mission and story of Umoja: uniting our people, science, and capabilities to bring our in vivo CAR T programs to clinical stage, all in service of broadening patient access and increasing effectiveness of life-saving CAR T cells.

At Umoja, we focus both on advancing our science in service of patients and on making a meaningful difference in the communities that we call home. In celebration of #GivingTuesday, we are proud to highlight the work done recently by our Colorado teams who partnered with Community Food Share in nearby Louisville. A heartfelt thank you to everyone at Umoja who have volunteered since 2022 in supporting our communities in Washington, Colorado, and beyond.

We are thrilled to announce Scott Myers as our new board chairman. Please join us in welcoming Scott to Umoja! Full details: https://lnkd.in/g_th3kRU